Affinity Asset Advisors LLC Raises Position in Nkarta, Inc. (NASDAQ:NKTX)

Affinity Asset Advisors LLC increased its stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 23.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 800,000 shares of the company's stock after buying an additional 150,000 shares during the quarter. Affinity Asset Advisors LLC owned 1.13% of Nkarta worth $1,992,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of NKTX. JPMorgan Chase & Co. lifted its position in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the period. Geode Capital Management LLC lifted its stake in shares of Nkarta by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock worth $2,942,000 after buying an additional 10,331 shares during the last quarter. State Street Corp grew its position in Nkarta by 1.4% during the third quarter. State Street Corp now owns 1,098,062 shares of the company's stock worth $4,963,000 after buying an additional 15,569 shares in the last quarter. Barclays PLC lifted its stake in Nkarta by 16.5% during the fourth quarter. Barclays PLC now owns 270,857 shares of the company's stock worth $674,000 after purchasing an additional 38,291 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Nkarta by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock worth $561,000 after acquiring an additional 8,883 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on NKTX. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a research note on Thursday, March 27th. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Nkarta in a research report on Wednesday, April 9th. Finally, Stifel Nicolaus dropped their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $14.86.

Nkarta Price Performance

NKTX stock traded up $0.06 during trading on Friday, reaching $1.81. The company had a trading volume of 523,623 shares, compared to its average volume of 1,095,981. Nkarta, Inc. has a 52 week low of $1.31 and a 52 week high of $8.33. The business has a 50 day moving average of $1.77 and a 200 day moving average of $2.46. The company has a market cap of $128.43 million, a P/E ratio of -0.96 and a beta of 0.83.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. Research analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.